Lifestyle interventions were the least effective treatment, the investigators found, producing a mean total body weight loss of 7.4% at the end of the treatment period, followed by a mean per-month weight regain of 0.14%, with participants reaching their pre-intervention weights within 4.1 years
revealed that the rates of neuropathies leading to first/recurrent amputation within 30 years were higher in patients receiving glimepiride 8 mg/day (N=248) than in patients receiving liraglutide 1.2 mg/day (N=251) or liraglutide 1.8 mg/day (n=247), while they were numerically similar between patients receiving liraglutide 1.2 mg/day and liraglutide 1.8 mg/day
The first several years of that commercial window are consumed by the slow ramp of physician adoption, payer negotiations, and market access challenges
Evidence indicates that weight reduction not only alleviates pain but also enhances physical function, underscoring its critical role in breaking the vicious cycle between these conditions [41,42,43,44]